RTP Mobile Logo

Interview with Prof John G Gribben, MD, DSc, FMedSci


Track 1: Case: A 73-year-old woman who presents with fatigue and cervical lymphadenopathy receives ibrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)
Track 2: Assessment of biomarkers to inform therapeutic decision-making for patients with CLL
Track 3: Perspective on watching and waiting versus treatment for patients with newly diagnosed CLL
Track 4: CLL12: An ongoing Phase III placebo-controlled trial of ibrutinib versus watch and wait for previously untreated Binet Stage A CLL in patients at risk of disease progression
Track 5: Case: A 49-year-old man with CLL with an IGHV mutation experiences profound fatigue and rash with fludarabine/cyclophosphamide/rituximab (FCR) as first-line therapy
Track 6: Minimal residual disease (MRD) status and prognosis for patients with CLL
Track 7: Response to ibrutinib as front-line therapy for CLL
Track 8: Risk of ibrutinib-associated hypertension and bleeding
Track 9: Selection and sequencing of treatment for CLL
Track 10: Results of the Phase III MURANO trial evaluating venetoclax/rituximab versus bendamustine/rituximab for relapsed/refractory CLL
Track 11: Assessing the risk of tumor lysis syndrome (TLS) with venetoclax
Track 12: Prevention and management of venetoclax-associated TLS
Track 13: Benefits and risks of the venetoclax/ibrutinib combination as potential up-front therapy for CLL
Track 14: Case: A 65-year-old man with FCR-refractory CLL who has a history of poorly controlled atrial fibrillation receives acalabrutinib on a clinical trial
Track 15: Use of acalabrutinib in patients with preexisting, poorly controlled atrial fibrillation
Track 16: Acalabrutinib-associated headaches
Track 17: Perspective on the use of venetoclax/rituximab as second-line therapy
Track 18: Risk of bleeding with Bruton tyrosine kinase (BTK) inhibitors and use for patients receiving anticoagulants
Track 19: Role of allogeneic transplant in the treatment of CLL
Track 20: Clinical presentation and management of hairy cell leukemia
Track 21: BRAF V600 mutations in hairy cell leukemia
Track 22: First-line therapy for patients with hairy cell leukemia
Track 23: Approach to therapy for patients with relapsed hairy cell leukemia
Track 24: Mechanism of action, efficacy and tolerability of the antibody-drug conjugate moxetumomab pasudotox for hairy cell leukemia

Interview with Jennifer R Brown, MD, PhD

Track 1: Viewpoint on observation versus initiation of treatment for patients with newly diagnosed CLL
Track 2: Comparison of efficacy and tolerability among BTK inhibitors
Track 3: Effects of deletion 17p and TP53 mutations on response to therapy
Track 4: IGHV mutation status as a prognostic and predictive biomarker
Track 5: Benefits and risks of FCR as first-line therapy for patients with CLL with IGHV mutations
Track 6: Correlation between MRD status and outcomes for patients with CLL
Track 7: Choice of obinutuzumab-based therapy in the first-line setting for CLL
Track 8: Use of ibrutinib for patients with previously untreated CLL
Track 9: Adherence to treatment with ibrutinib and reasons for discontinuation
Track 10: Efficacy and side-effect profile of acalabrutinib
Track 11: Incidence of acalabrutinib-associated atrial fibrillation and headaches
Track 12: Treatment options for patients who experience disease progression on ibrutinib
Track 13: Clinical implications of the MURANO trial investigating venetoclax/rituximab for relapsed/refractory CLL
Track 14: Monitoring and prophylaxis for venetoclax-associated TLS
Track 15: Activity and tolerability of PI3 kinase inhibitors in CLL
Track 16: Perspective on the efficacy of ibrutinib with venetoclax
Track 17: Role of obinutuzumab with venetoclax for previously untreated CLL
Track 18: Benefits and risks of ibrutinib with FCR
Track 19: Case: A 75-year-old woman with relapsed CLL/small lymphocytic lymphoma with del(13q) and unmutated IGHV achieves an excellent response to venetoclax on a clinical trial
Track 20: Sequencing of treatment for patients with relapsed/refractory CLL
Track 21: Case: An 85-year-old woman with relapsed CLL with del(13q) experiences recurrent congestive heart failure after receiving ibrutinib
Track 22: Case: A 65-year-old man with CLL with unmutated IGHV and a TP53 mutation receives acalabrutinib as second-line therapy
Track 23: Case: A 49-year-old man with CLL with unmutated IGHV and del(13q) achieves an MRD-negative complete remission on venetoclax and obinutuzumab
Track 24: Approach to TLS prevention for patients receiving venetoclax
Track 25: Case: A 90-year-old man presents with loss of vision and is diagnosed with CLL with unmutated IGHV and del(11q)
Track 26: Emerging data with checkpoint inhibitors for Richter’s transformation
Track 27: Efficacy of chimeric antigen receptor (CAR) T-cell therapy for CLL
Prof John G Gribben, MD, DSc, FMedSci
Chair of Medical Oncology
Barts Cancer Institute
Queen Mary University of London
Charterhouse Square
London, United Kingdom
Jennifer R Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Neil Love, MD
Research To Practice
Miami, Florida